Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply

Aliment Pharmacol Ther. 2022 May;55(9):1220-1221. doi: 10.1111/apt.16917.

Authors

Vivek C Goodoory^{1

2}, Cho Ee Ng³, Christopher J Black^{1

2}, Alexander C Ford^{1

2}

Affiliations

¹ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
² Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
³ County Durham and Darlington NHS Foundation Trust, Durham, UK.

PMID: 35429032
DOI: 10.1111/apt.16917

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Irritable Bowel Syndrome*